Evidence map›Paper›PMID 40077899›Full record

ArticleJournal of diabetes investigation2025

Characterization of treatment intensified (add-on to metformin) adults with type 2 diabetes in Thailand: A cross-sectional real-world study (CONVERGE).

Chutintorn Sriphrapradang, Ammarin Thakkinstian, Ratiporn Chinthammit, Gurudutt Nayak

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of diabetes investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Chutintorn SriphrapradangDivision of Endocrinology and Metabolism, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.ORCID https://orcid.org/0000-0001-8294-8601
Ammarin ThakkinstianDepartment of Clinical Epidemiology and Biostatistics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.ORCID https://orcid.org/0000-0001-9991-386X
Ratiporn ChinthammitNovo Nordisk Pharma, Bangkok, Thailand.
Gurudutt NayakNovo Nordisk Pharma, Bangkok, Thailand.

Funding

Novo Nordisk Pharma
6 · The paper itself

Abstract

objectiveThe CONVERGE (Cardiovascular Outcomes and Value in the Real-World with GLP-1RAs) study characterized demographics, clinical characteristics, and medication use in treatment-intensified (add-on to metformin) adults with type 2 diabetes (T2D) in Thailand.

methodsA retrospective cross-sectional study of data from medical records (Jul 26, 2013, to Dec 31, 2017) was descriptively summarized for overall population and subgroups defined by glucose-lowering agent (GLA) classes.

resultsData from 1,000 adults were collected in reverse chronological order. At baseline, the mean (SD) age was 60 (12) years, HbA

conclusionsThese results indicate low utilization of GLAs with CV benefits, attributed to a lack of CV benefit data during the study period and partial reimbursement implementation. Future studies must identify barriers to adoption and estimate the usage of these GLAs with CV benefits as more evidence becomes available on positive CV outcomes to improve patient care in Thailand.

Indexed as

BiomarkersDiabetes Mellitus, Type 2Hypoglycemic AgentsMetforminAdultAgedCross-Sectional StudiesDrug Therapy, CombinationFemaleFollow-Up StudiesGlycated HemoglobinHumansMaleMiddle AgedPrognosisRetrospective StudiesBiomarkersGlycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic AgentsMetforminSodium-Glucose Transporter 2 InhibitorsGlucagon‐like peptide‐1 receptor agonistsReal worldTreatment patterns

Identifiers

PMID40077899
PMCPMC12131932

What Socratic holds

Texttitle and abstract
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.